ACE in the hole {#cesec10}
===============

Findings from a study in monkey and human cells suggests that an experimental respiratory drug might be effective against severe acute respiratory syndrome coronavirus 2 ([SARS-CoV-2](https://www.cell.com/pb-assets/products/coronavirus/CELL_CELL-D-20-00739.pdf){#interrefs10}) infection. The drug, APN01, is a soluble, recombinant version of the surface receptor the virus uses to enter human cells, angiotensin converting enzyme 2 (ACE2). By flooding a culture of monkey-derived Vero cells with the drug, viral replication was reduced by a factor of 1000--5000. The researchers then showed that APN01 could inhibit viral replication in human blood vessel and kidney organoids (three-dimensional cell cultures derived from stem cells). By binding to and mopping up virus that would otherwise infect cells, the researchers think APN01 has promise in treating early-stage COVID-19 disease.

Clues in the cell {#cesec20}
=================

As well as the surface receptor ACE2, SARS-CoV-2 needs co-factors to successfully infect cells. Findings from a [small study of lung tissue cells](https://doi.org/10.15252/embj.20105114){#interrefs20} from 16 people (initially collected as part of a lung cancer study) suggest that both ACE2 and the cofactor TMPRSS2 are highly expressed in progenitor cells that go on to form respiratory tract cells. The abundance of ACE2 proteins in these cells increased with age and seemed to be greater in men than women, reflecting the epidemiology of the disease, which seems to more seriously affect older people and more often men than women.

The crown slips {#cesec30}
===============

In experiments in mice engineered to be susceptible to Middle East respiratory syndrome coronavirus ([MERS-CoV](https://doi.org/10.1128/mBio.00554-20){#interrefs30}), researchers have identified a vaccine against the virus, noting that the vaccine strategy also holds promise against other dangerous coronaviruses. As a vector, the vaccine uses parainfluenza virus (PIV5) expressing the MERS-CoV envelope spike protein. One intranasal dose gave mice full protection against an otherwise lethal dose of MERS-CoV given 4 weeks after vaccination, mainly through T-cell-based immunity. The technology holds promise as an effective immunisation strategy because PIV5 can infect people without causing disease. A version of the vaccine to prevent disease caused by SARS-CoV-2 is being tested now.

In-*Tox*-icated {#cesec40}
===============

Like tiny football hooligans chanting at mounted police, mice infected with *Toxoplasma gondii* can be seen taunting cats. The parasite, which must pass back to the cat\'s gut to complete its lifecycle, interferes with the mouse\'s brain signaling to remove inhibition and normal survival instincts. People infected with *T gondii* have similar [neuropsychiatric symptoms](https://doi.org/10.1002/glia.23816){#interrefs40}, as well as seizures. An electron microscopy study in brain tissue samples from people who had been infected showed that the chronic infection causes a loss of inhibitory synapses and an unsheathing of other neurons by microglia, with similar histological patterns seen in other psychiatric disorders.

*S aureus* stresses over study {#cesec50}
==============================

[To preserve energy under stress](https://doi.org/10.1038/s41467-020-15517-0){#interrefs50}---be it from antibiotics or host immunity ---*Staphylococcus aureus* halts its production of proteins. To do this, it expresses a protein called ribosome silencing factor S (RSfS). However, due to the inherent difficulties in biologically producing a protein that itself halts protein production, researchers have not been able to to find out exactly how RSfS works. Using cryoelectron microscopy and X-ray diffraction methods, European researchers isolated and captured the protein in complex with the large subunit of the bacterial ribosome. The protein, it seems, stops the smaller ribosomal subunit from joining and forming functional ribosomes. Further understanding of this mechanism might lead to the development of new antibiotics.

Sickle cell and HIV {#cesec60}
===================

Findings from a new study have added weight to previous suggestions that people with sickle-cell anaemia have a lower risk of [HIV](https://doi.org/10.1371/journal.pone.0218880){#interrefs60} infection than otherwise healthy people---but it was unable to pin down the mechanistic explanation as to why. Researchers retrospectively reviewed data from an HIV transfusion risk study done in 1985--93 and confirmed that individuals with sickle-cell anaemia were indeed at lower risk of HIV infection. In further laboratory studies, they showed that CD4+ cells from people with sickle cell disease had less CCR5 (a key protein in HIV infection) and more CD4 protein than did cells form otherwise healthy people, but no increased susceptibility to HIV.

An evolving model {#cesec70}
=================

A team of US mathematicians and computer scientists have proposed a [new model to predict the spread of future infectious diseases](https://doi.org/10.1073/pnas.1918529117){#interrefs70}. The model, based on how misinformation spreads and changes as it travels through populations, accounts for mutations in the pathogen as it passes from person to person and group to group---and how it evolves in response to environmental conditions (eg, social distancing) and medical interventions. By contrast, say the scientists, traditional models do not account for such evolution and thus fall short of real-time usefulness. They say their model would allow public health practitioners dynamism when selecting interventions during an ongoing outbreak.
